The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Hims & Hers Health, Inc. HIMS shares rallied 10.1% in the last trading session to close at $19.44. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.77 which represents a slight increase of $0.06 or 0.34% from the prior close of $17.71. The stock opened at ...